Minzhi Li

Minzhi Li

Auto-generated profile, based on publicly available information

Minzhi Li

Department of Dermatology, Zhongshan Hospital of Traditional Chinese Medicine, Guangzhou 528400, China

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy
Verified
Journal Article
Closed access
XJXilang Jin
Xilang Jin
XMXuehao Ma
Xuehao Ma
HZHongwei Zhou
Hongwei Zhou
JCJiawei Chen
Jiawei Chen
MLMinzhi Li
Minzhi Li
MSMengyao She
Mengyao She

1 September 2017 in Applied Catalysis A: General
Verified
Journal Article
Closed access
XLXu Liang
Xu Liang
THTingting Huang
Tingting Huang
MLMinzhi Li
Minzhi Li
JMJohn Mack
John Mack
MWMartijn Wildervanck
Martijn Wildervanck
WZWeihua Zhu
Weihua Zhu

1 May 2016 in Journal of Porphyrins and Phthalocyanines
Verified
Journal Article
Closed access
LXLi Xu
Li Xu
THTingting Huang
Tingting Huang
XLXu Liang
Xu Liang
JMJohn Mack
John Mack
JHJessica Harris
Jessica Harris
WZWeihua Zhu
Weihua Zhu

19 April 2023 in Journal of Pharmaceutical and Biopharmaceutical Research
Verified
Journal Article
Open access
PDF file
XWXiaowen Wen
Xiaowen Wen
SCShaokang Cui
Shaokang Cui
MLMinzhi Li
Minzhi Li
YZYongping Zheng
Yongping Zheng
HXHaoyou Xu
Haoyou Xu
Objective: Fuyuekang Lotion (FYKL) is an improved traditional Chinese medicine (TCM) prescription widely used to treat acute eczema (AE). However, the mechanism of action remains unclear. This study aimed to explore the therapeutic mechanism of FYKL in AE.Methods: We revealed the underlying mechanism by utilizing a network pharmacology approach, molecular docking studies, and in vitro verification. The active compounds in FYKL were identified, and their targets were predicted. These targets were subsequently mapped to a component-target interaction network, with their therapeutic mechanisms predicted through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. Molecular docking was used to verify protein-binding efficacy. Potential key targets of FYKL against AE were further confirmed via reverse transcription quantitative polymerase chain reaction (RT-qPCR).Results: The study identified 59 potential active compounds of FYKL, with quercetin, luteolin, and gallic acid suggested as critical active ingredients. Our findings suggest that these ingredients could exert their effects mainly by modulating the inflammatory immune response and promoting epidermal repair. FYKL was found to be a multi-target, multi-component drug that could potentially regulate the inflammatory immune response in AE through numerous pathways.Conclusions: The findings from this study provide a scientific basis for further research into the therapeutic effects and mechanisms of FYKL in treating AE, underscoring the potential of TCM in modern therapeutics.